Related Experiment Video

Updated: Jun 19, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Denileukin diftitox: a novel immunotoxin

George Manoukian1, Fred Hagemeister

  • 1University of Texas at Houston - Internal Medicine, Houston, Texas 77030, USA.

Expert Opinion on Biological Therapy
|October 13, 2009
PubMed
Abstract

Insights

Denileukin diftitox (Ontak) is FDA-approved for cutaneous T-cell lymphoma and shows promise for various cancers and autoimmune diseases. Further human trials are needed to confirm its efficacy across a broader range of conditions.

Area of Science:

  • Immunotherapy
  • Oncology
  • Dermatology

Background:

  • Denileukin diftitox (Ontak) is a fusion protein approved by the FDA.
  • Its primary indication is for CD25-positive cutaneous T-cell lymphoma (CTCL).

Purpose of the Study:

  • To review the FDA-approved and potential therapeutic applications of denileukin diftitox.
  • To explore its efficacy in both neoplastic and non-neoplastic conditions.

Main Methods:

  • Literature review of journal articles.
  • Internet-based information retrieval.

Main Results:

  • Ontak is FDA-approved for CD25-positive CTCL.
  • Investigated for CD25-negative T-cell lymphoma, chronic lymphocytic leukemia (CLL), non-Hodgkin's B-cell lymphoma (NHL), and adult T-cell leukemia/lymphoma (ATL).
  • Potential uses include graft-versus-host disease (GvHD), psoriasis, rheumatoid arthritis (RA), systemic lupus, scleroderma, vasculitis, hepatocellular carcinoma (HCC), and HIV.

Conclusions:

  • Denileukin diftitox exhibits potential for treating numerous malignant and benign disorders.
  • Additional human clinical trials are necessary to validate its efficacy for a wider spectrum of diseases.

More Related Videos

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...